The EDEM2 Knockout A-549 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human A-549 lung carcinoma epithelial cell line. This product features targeted disruption of the EDEM2 gene, which encodes a critical component of the endoplasmic reticulum-associated degradation (ERAD) machinery. The polyclonal format provides a heterogeneous pool of knockout cells, enabling population-level studies without the selection bias associated with single-cell clones. This model serves as a versatile loss-of-function tool for investigating ER protein quality control in a lung adenocarcinoma context.
The parental A-549 cell line is a widely used in vitro model of human lung adenocarcinoma, originally isolated from a patient tumor. These adherent epithelial cells retain characteristics of alveolar type II pneumocytes and have been extensively employed to study lung cancer biology, drug metabolism, and host?Cpathogen interactions. Their robust growth and well-characterized signaling networks make them an ideal host for studying the impact of genetic perturbations on tumor cell physiology, including stress responses and apoptotic pathways.
EDEM2 acts as an ER lectin that specifically recognizes mannose-trimmed N-glycans on terminally misfolded glycoproteins. Upon substrate binding, EDEM2 facilitates the delivery of these aberrant proteins to the HRD1-SEL1L ubiquitin ligase complex, which mediates their retrotranslocation to the cytosol, ubiquitination, and subsequent proteasomal degradation. This process is a central arm of the ERAD pathway, functionally linked to cofactors such as OS-9 and XTP3-B and the calnexin/calreticulin chaperone cycle. EDEM2 expression is transcriptionally upregulated by the unfolded protein response (UPR) through the actions of XBP1s and ATF6, which are activated upon ER stress. By promoting clearance of misfolded glycoproteins, EDEM2 directly alleviates ER burden and maintains cellular proteostasis.
In the context of A-549 lung adenocarcinoma cells, EDEM2 knockout provides a physiologically relevant platform to dissect the interplay between ER proteostasis and tumor cell behavior. Lung cancer cells frequently experience heightened ER stress due to rapid proliferation, hypoxia, and oncogenic activation, potentially rendering them dependent on ERAD for survival. Disruption of EDEM2 is expected to impair glycoprotein quality control, leading to accumulation of misfolded proteins and chronic UPR activation, which may sensitize cells to proteotoxic insults or alter their proliferative capacity. This polyclonal population allows assessment of these effects at a population level, capturing the heterogeneity inherent in tumor cell responses.
Key research applications include monitoring UPR activation through western blotting for markers such as BiP and CHOP, quantifying XBP1 splicing via RT-qPCR, and assessing cell viability under tunicamycin-induced ER stress. Flow cytometry using Annexin V staining can detect apoptosis, while colony formation assays gauge long-term proliferation effects. Drug sensitivity testing with proteasome inhibitors like bortezomib can reveal the contribution of EDEM2 to therapeutic resistance. This product is well-suited for mechanistic studies of ERAD deficiency and ER stress signaling in lung adenocarcinoma models. For further information or technical support, please contact Ascent Research.
